Ferronova is an Australian biotechnology company commercialising magnetic nanoparticle and molecular imaging, that can be applied to a variety of medical applications. Their first-generation product is a combination device/drug system intended to aid in more accurate staging of solid tumour cancers. Ferronova’s mission is to ensure no cancer goes undetected. They aim to enable surgeons, oncologists and pathologists to maximise the use of their skills, support less invasive procedures and improve overall patient outcomes.